Document is current
Any future updates will be listed below
-
Authors
Ninmer, Emily K.
Xu, Feifan
Slingluff, Craig L. Jr.
-
Funding
Funding for this research was provided by:
Rebecca Harris Fellowship
- License Information
-
More Information
Article History
Received: 7 October 2024
Accepted: 1 December 2024
First Online: 20 December 2024
Disclosure
: C.L.S. has the following disclosures: Research support to the University of Virginia from Celldex (funding, drug), Glaxo-Smith Kline (funding), Merck (funding, drug), 3M (drug), Theraclion (device staff support); Funding to the University of Virginia from Polynoma for PI role on the MAVIS Clinical Trial; Funding to the University of Virginia for roles on Scientific Advisory Boards for Immatics and CureVac. Also, C.L.S. has received licensing fee payments through the UVA Licensing and Ventures Group (UVA LVG) for patents for peptides used in cancer vaccines, including United States Patent # 6,660,276; 6,558,671; and 7,019,112; however, the terms of those patents have expired. He holds other patents for peptides in melanoma vaccines (US Patent number US 9,345,755 B2), plus one submitted, all managed by UVA LVG. There are no other disclosures or competing interests for the other authors.
